BetaEntity Annotation Prototype
← Back to diseases

Annotated abstract

61 Transcatheter edge-to-edge repair for tricuspid regurgitation – initial experience from an Irish centre

heartjnl · 2025-10-14 · canonical JSON source

9 visible annotations · policy: published · automated confidence ≥ 75.00%

Document resource

Introduction Tricuspid regurgitation (TR) is predominantly secondary in aetiology, but epidemiological studies identify it as a strong independent predictor of mortality. Transcatheter edge-to-edge repair (TEER) offers a promising option for patients with severe TR who are at high or prohibitive risk for surgery. We evaluated the procedural and in-hospital outcomes of TEER for TR at our centre.Methods Patients who underwent tricuspid valve (TV) TEER were prospectively identified. Baseline clinical and echocardiographic data, along with procedural and in-hospital outcomes were recorded in a dedicated Transcatheter Mitral and Tricuspid Valve Registry (Dendrite Clinical Systems).Results Between April 2022 and April 2025, 32 patients underwent TV TEER. Baseline patient characteristics are presented in table 1, and the aetiology of TR is summarized in figure 1. A TEER device was successfully implanted in 29 of 32 patients (91%). The Edwards Pascal and Abbott TriClip systems were used in 24 (83%) and 5 (17%) patients, respectively. The median number of devices implanted per case was 2 (IQR: 2–2). The most common deployment involved one device between the antero-septal leaflets and another between the postero-septal leaflets (image 1). Mean procedural duration was 116 ± 48 minutes and mean fluoroscopy time was 27 ± 15 minutes. Among patients who received a TEER device (n=29), 26 (90%) had a ≥2-grade TR reduction, and 24 (83%) had a post-procedure TR grade of moderate or less. In the entire cohort (n=32), 81% had a ≥2-grade reduction and 75% had a TR grade of moderate or less (image 2). Median duration of hospital stay was 5 (IQR: 4–7). No procedure-related or in-hospital adverse events or deaths occurred.Conclusion This initial experience demonstrates that TV TEER is feasible, safe, and associated with high procedural success. Long-term follow-up is needed to assess durability and impact on hard clinical outcomes.Abstract 61 Table 1Baseline patient characteristics (N=32)Abstract 61 Figure 1Baseline patient characteristics (N=32)Abstract 61 Image 1Device deployment locationAbstract 61 Image 2Change in TR grade (N=32)